Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy that researchers believe is not curable using current standard approaches. However, researchers developed a bispecific CAR T-cell therapy targeting both CD20 and CD19 cells induced a 92% complete response (CR) rate at 90 days in patients with relapsed/refractory MCL. In the study, researchers administered CAR T cells at a fixed dose of 2.5 x 10 6 cells/kg to 14 patients with MCL. At day 28, the overall response rate (ORR) was 100% with a CR rate of 71%. The minimal residual disease (MRD) negativity rate on days 28 to 65 (n = 12) was 75%. Twelve patients were evaluable for response on day 90; here, the ORR remained at 100%. The CR rate of 92% met the predefined efficacy criteria for further clinical investigation. Eleven patients moved on to the phase 2 trial.
